Business

SELLAS Life Sciences shares rise 156% after positive cancer vaccine trial results

· 1 source · Bihar edition

This story has no audio yet

Shares of SELLAS Life Sciences Group, a pharmaceutical company headquartered in New York and listed on Nasdaq, rose 156 per cent on Tuesday, closing at 19.15 dollars against 7.99 dollars on November 16. The stock opened above 24 dollars and briefly touched 24.89 dollars, a new 52-week high. The rally followed the company's report of positive trial results for a cancer vaccine.

The vaccine, galinpepimut-S or GPS, was tested on 126 patients with acute myeloid leukaemia who had gone into remission after cancer therapy but could not undergo bone marrow or stem-cell transplants. The company said GPS cut the risk of death by 41 per cent compared with the best available treatment. Vaccinated patients lived on average 24 months, against 14.7 months for the control group.

Reports said the company makes cancer-related drugs, and the vaccine may considerably reduce the risk linked to blood cancer. An illustrative 10,000-dollar investment at the start of the day would have grown to about 25,600 dollars. The article advised readers to consult market experts before investing.

Key points

  • SELLAS Life Sciences shares closed up 156 per cent on Tuesday at 19.15 dollars.
  • The rally followed positive trial results for the company's cancer vaccine, GPS.
  • The company said GPS cut the risk of death by 41 per cent in a trial of 126 patients.
  • Vaccinated patients lived about 24 months on average, against 14.7 months for the control group.

Coverage from

This story was put together automatically from the sources above. Open a source to read its original report. How nuze makes stories